Janelsins et al.‎ [29]

Longitudinal

BC CH+

(n = 580)

HC

(n = 363)

10-point Likert scale; modified MD Anderson Symptom Inventory‎ [31]

Difference in mean score(SE) trajectory between exposure and control:

- From pre-treatment to post-treatment: 1.15 (0.14) (95% CI 0.88 - 1.42; p < 0.001)

- From post-treatment to 6-month follow-up: 0.86 (0.14) (95% CI 0.58 - 1.13; p < 0.001)

Difference in mean score(SE) trajectory between exposure and control:

- From pre-treatment to post-treatment: 0.99 (0.15) (95% CI 0.7 - 1.28; p < 0.001)

- From post-treatment to 6 -month follow-up: 0.52 (0.15) (95% CI 0.22 - 0.81; p < 0.001)

Difference in mean score(SE) trajectory between exposure and control:

- From pre-treatment to post-treatment: 1.24 (0.17) (95% CI 0.92 - 1.57; p < 0.001)

- From post-treatment to 6-month follow-up: 0.84 (0.17) (95% CI 0.50 - 1.17; p < 0.001)

n/a

Janelsins et a‎l. [30]

Longitudinal

BC CH+

(n = 581)

HC

(n = 364)

FACT-COG

n/a

n/a

n/a

Change in mean (SD) score from pre-treatment to post-treatment:

- CH+:

-15.9 (30.86) (p < 0.001)

- CH−:

+1.4 (16.38) (p = 0.122)

Change in mean (SD) score from pre-treatment to 6 – month follow-up:

- CH+:

−10.4 (31.41) (p < 0.001)

- CH−:

+1.5 (16.31) (p = 0.1)

Kohli et al.‎ [32]

Longitudinal

Various Solid Malignancies

CH+;

(n = 595)

n/a*

11 – point Likert scale; modified MD Anderson Symptom Inventory [7]

Baseline = 54.5%

During treatment = 81.8%

6 months post-treatment = 76.4%

Baseline = 55.9%

During treatment = 85.9%

6 months post-treatment = 68.6%

n/a

n/a

Tager et al.‎ [33]

Longitudinal

BC;

CH+

(n = 61)

BC;

CH−

(n = 31)

5-Point Likert Scale

27% vs 32% before treatment;

43% vs 35% at 6 months post-treatment;

46% vs 31% at 6 months follow-up

n/a

n/a

n/a